ZMYND11 and prostate carcinoma: Consistent with these findings, a Kaplan-Meier analysis of our TMA immunostaining results showed that prostate cancer patients with lower protein levels of ZMYND11 had a significant shorter overall survival time compared to patients with higher levels of ZMYND11 expression (Fig. 1i).